OTCMKTS:AIMD Ainos (AIMD) Stock Price, News & Analysis $0.45 +0.01 (+2.50%) (As of 12/20/2024 05:51 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsFinancialsHeadlinesSEC Filings About Ainos Stock (OTCMKTS:AIMD) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Ainos alerts:Sign Up Key Stats Today's Range$0.44▼$0.4650-Day Range$0.43▼$0.5752-Week Range$0.40▼$4.29Volume34,535 shsAverage Volume879,979 shsMarket Capitalization$6.24 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAinos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.Read More… Receive AIMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ainos and its competitors with MarketBeat's FREE daily newsletter. Email Address AIMD Stock News HeadlinesAinos, Inc.: CORRECTION BY SOURCE: Smell the Future: Ainos Elevates Health and Technology With AI Nose and VELDONADecember 18, 2024 | finanznachrichten.deAnalyzing Ainos (OTCMKTS:AIMD) and Nova Eye Medical (OTCMKTS:ELXMF)December 15, 2024 | americanbankingnews.comVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.December 22, 2024 | Porter & Company (Ad)Ainos Inc. secures stockholder nod for special stock awardsOctober 3, 2024 | investing.comAinos, Inc.: Water Tower Research Highlights Ainos VELDONA Clinical Trial for HIV+ Patients with Oral WartsSeptember 20, 2024 | finanznachrichten.deWhy Is Ainos (AIMD) Stock Up 38% Today?August 12, 2024 | msn.comAinos, Inc.: Ainos to Initiate Clinical Study of New Potential VELDONA-Based Animal Drug, Expanding VELDONA's Potential MarketMay 15, 2024 | finanznachrichten.deSOS, MFG and LYT among pre-market losersMarch 11, 2024 | msn.comSee More Headlines AIMD Stock Analysis - Frequently Asked Questions How have AIMD shares performed this year? Ainos' stock was trading at $2.05 at the beginning of 2024. Since then, AIMD shares have decreased by 78.0% and is now trading at $0.4511. View the best growth stocks for 2024 here. When did Ainos' stock split? Ainos's stock reverse split on Tuesday, August 9th 2022. The 1-15 reverse split was announced on Tuesday, August 9th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, August 9th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. How do I buy shares of Ainos? Shares of AIMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Ainos own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ainos investors own include CRISPR Therapeutics (CRSP), Iovance Biotherapeutics (IOVA), Vistagen Therapeutics (VTGN), Alpha Lithium (APHLF), Baidu (BIDU), DiDi Global (DIDIY) and Kingsoft Cloud (KC). Company Calendar Today12/22/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Medical Devices Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:AIMD CUSIPN/A CIK1014763 Webwww.amarbio.com Phone(858) 869-2986Fax806-376-9301Employees40Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,010,000.00 Net Margins-515.80% Pretax Margin-515.76% Return on Equity-44.32% Return on Assets-40.35% Debt Debt-to-Equity Ratio0.08 Current Ratio1.92 Quick Ratio1.45 Sales & Book Value Annual Sales$40,633.00 Price / Sales153.64 Cash FlowN/A Price / Cash FlowN/A Book Value$1.50 per share Price / Book0.30Miscellaneous Outstanding Shares13,839,000Free Float13,322,000Market Cap$6.24 million OptionableNot Optionable Beta1.42 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (OTCMKTS:AIMD) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ainos, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ainos With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.